Advertisement
Advertisement
U.S. Markets close in 3 hrs 39 mins
Advertisement
Advertisement
Advertisement
Advertisement

Evaxion Biotech A/S (EVAX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.6400+0.0300 (+1.86%)
As of 12:12PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6100
Open1.6100
Bid1.6400 x 1100
Ask1.6600 x 900
Day's Range1.6100 - 1.6784
52 Week Range1.4100 - 3.5200
Volume124,639
Avg. Volume319,105
Market Cap37.952M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Evaxion receives FDA fast-track designation for personalized cancer immunotherapy

    COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for the Company’s personalized cancer therapy, EVX-01, in combination with KEYTRUDA®.In December 2022, Evaxion received FDA approval to proceed with its Phase 2b clinical trial,

  • GlobeNewswire

    Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

    COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01. In November 2022, the Company submitted an Investigational New Drug Application (“IND”) along with a Fast Track designation appl

  • GlobeNewswire

    Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

    COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023. By mid-2023, Evaxion will present the full clinical readout of EVX-01 in metastatic melanoma

Advertisement
Advertisement